SpyGlass Versus ESWL for Large Common Bile Duct Stones
Launched by FIRST PEOPLE'S HOSPITAL OF HANGZHOU · Jan 10, 2022
Trial Information
Current as of August 30, 2025
Completed
Keywords
ClinConnect Summary
ESWL was first used for the removal of renal calculi and ureteral calculi however, now a day is being used for biliary calculi. It has the advantages of simple operation, low cost, and higher safety. Recent studies show that the procedure time for ESWL is also shorter and the utilization rate of mechanical lithotripsy was effectively reduced with fewer complications. But It is difficult for ESWL to break the stones larger than 3cm into small pieces. So SpyGlass-guided laser lithotripsy is used. Spyglass has been used in clinics for more than ten years. Recently, a study reported difficult b...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • large bile duct stones (≥10 mm)
- Exclusion Criteria:
- • pregnancy
- • refusal of written informed consent
- • Patients with benign or malignant biliary stricture
- • Contraindications to ERCP exist
- • Complicated with acute pancreatitis or acute cholangitis
- • Coagulation dysfunction#thrombocytopenia
- • Patients after gastrointestinal reconstruction
About First People's Hospital Of Hangzhou
First People's Hospital of Hangzhou is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong focus on patient-centered care, the hospital integrates cutting-edge medical technology with a team of experienced professionals to enhance treatment outcomes. Committed to scientific excellence, the institution actively collaborates with researchers and pharmaceutical companies to facilitate the development of new therapies and improve clinical practices. Its state-of-the-art facilities and commitment to ethical standards make First People's Hospital of Hangzhou a pivotal player in the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Jianfeng Yang, Doctor
Principal Investigator
Affilated Hangzhou First People Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials